Observational studyInternational ophthalmology2026
Glaucoma spectrum findings among the Yanomami Indigenous people of the Brazilian Amazon.
Observational study in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study provides the first systematic characterisation of IOP, optic disc C/D ratio, and fundoscopic findings in the Yanomami, one of the largest and most geographically isolated Indigenous peoples of the Amazon, and identifies findings suggestive of glaucoma.
methodsCross-sectional observational study conducted June-August 2024 at the Yanomami Indigenous Health House (CASAI-Y), Boa Vista, Brazil. One hundred fifty-eight self-identified Yanomami individuals aged ≥ 5 years were examined. Non-contact tonometry (Huvitz HNT-7000), portable non-mydriatic fundus photography (Eyer), portable slit-lamp biomicroscopy, and direct ophthalmoscopy were performed. C/D ratio was graded by fundus photographic review. Associations were assessed by OR with 95% CI, Student t test, one-way ANOVA, Fisher exact test, and Spearman and Pearson correlation. P values were adjusted for multiple comparisons using the Benjamini-Hochberg procedure.
resultsAmong 151 participants with assessable IOP (secondary glaucoma case excluded from descriptive analysis), mean IOP was 13.64 mmHg (SD 1.59) OD and 13.93 mmHg (SD 1.75) OS; ocular hypertension was identified in 1 participant (0.66%). Mean C/D ratio was 0.261 (SD 0.129) OD and 0.267 (SD 0.138) OS among 148 participants; 3 (2.03%) had C/D > 0.5 in at least one eye. No significant IOP-C/D correlation was found (Spearman rₛ = 0.105, P = .210 OD; rₛ = 0.058, P = .496 OS). Secondary angle-closure glaucoma was confirmed in one participant (IOP 35/55 mmHg, 360° synechiae, no light perception). Two further participants had findings suggestive of primary glaucoma. Ocular trauma was associated with retinal cicatricial lesions (OR 13.41; 95% CI 2.55-70.35; P = .008; P adj = .036) and, without retaining significance after adjustment for multiple comparisons, with fundoscopic abnormality (OR 7.98; 95% CI 1.26-50.55; P = .04; P adj = .10); both estimates rest on 7 trauma-exposed participants. No diabetic retinopathy was identified.
conclusionsThis study provides the first quantitative ophthalmic baseline for the Yanomami regarding IOP, optic disc morphology, and fundoscopic findings. Primary open-angle glaucoma does not appear to constitute a relevant burden. Secondary glaucoma from complicated cataract is the most preventable severe presentation. Angle-closure glaucoma remains uncharacterised. Cataract surgical access, camerular angle screening, and glaucoma investigation are unmet priorities in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.